Jason Amello Candel Therapeutics, Inc. (CADL) insider trading activity

CADL Quotes by TradingView

Jason Amello is Chief Financial Officer of Candel Therapeutics, Inc.. Currently has a direct ownership of 202,009 shares of CADL, which is worth approximately $977,723. The most recent transaction as insider was on Nov 28, 2023, when has been sold 20,153 shares (Common Stock) at a price of $0.9 per share, resulting in proceeds of $18,137. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 202K
0% 3M change
9.07% 12M change
Total Value Held $977,723

Jason Amello Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 28 2023
SELL
Payment of exercise price or tax liability
$18,137 $0.9 p/Share
20,153 Reduced 9.07%
202,009 Common Stock
Nov 26 2023
BUY
Grant, award, or other acquisition
-
125,717 Added 36.14%
222,162 Common Stock
Dec 09 2022
BUY
Open market or private purchase
$4,763 $1.93 p/Share
2,468 Added 30.71%
5,568 Common Stock
Dec 08 2022
BUY
Open market or private purchase
$5,239 $1.69 p/Share
3,100 Added 50.0%
3,100 Common Stock
Nov 28 2022
BUY
Grant, award, or other acquisition
-
90,877 Added 50.0%
90,877 Common Stock

Also insider at

ACER
Acer Therapeutics Inc. Healthcare
Director
TCRX
TScan Therapeutics, Inc. Healthcare
Chief Financial Officer
JA

Jason Amello

Chief Financial Officer
Needham, MA

Track Institutional and Insider Activities on CADL

Follow Candel Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CADL shares.

Notify only if

Insider Trading

Get notified when an Candel Therapeutics, Inc. insider buys or sells CADL shares.

Notify only if

News

Receive news related to Candel Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CADL